Some are, including GLP-1 receptor agonists (semaglutide, tirzepatide), insulin, and a range of hormone-based therapeutics
A common protocol, for example, is to begin with about 20 mg of NAD+ (corresponding to a small volume from the vial, typically around 0.1 mL depending on concentration) administered subcutaneously and gradually increase the dose over subsequent injections up to around 100 mg per injection
Due to the Coronavirus (COVID-19) outbreak worldwide, the global demand for some Personal Protective Equipment (PPE) is exceeding current supply availability
Tripeptides such as GHK-Cu have an established safety record in topical and cosmetic applications, showing low cytotoxicity and reduced skin irritation compared with other copper compounds, and acceptable tolerability in clinical cosmetic studies [23, 74, 93]